对HPV16的人类单克隆抗体显示出共同的发育途径和公共表位的证据
Joseph J Carter1,2, Nicholas K Hurlburt1,3, Erin M Scherer1,2
1Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
PLoS pathogens
|October 21, 2025
概括
人类乳头瘤病毒 (HPV) 抗体向L1囊蛋白的特定环节. 对于中和,FG循环最为关键,但其他循环对于不同的人类单克隆抗体 (mAbs) 也很重要.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
背景情况:
- 人类乳头瘤病毒 (HPV) 感染是导致宫癌和其他癌症的主要原因.
- 针对HPV L1囊蛋白的抗体对于疫苗诱导的免疫是至关重要的.
- L1蛋白表面环是中和抗体的关键目标,但它们的具体作用各不相同.
研究的目的:
- 为了确定HPV16 L1囊蛋白的哪些表面环,需要被人类单克隆抗体 (mAbs) 中和.
- 描述疫苗接种后产生的HPV16特定mAbs的分子特征.
- 调查主导的mAb类型的结合表位和中和的结构基础.
主要方法:
- 68个HPV16特定的人类单克隆抗体 (mAbs) 的生成和表征.
- 使用嵌合式HPV16伪病毒 (cpsV) 与替代的表面循环来确定中和特异性.
- 低温电子显微镜 (Cryo-EM) 用于确定mAb-L1相互作用的结构.
主要成果:
- HPV16-FG循环最常被需要通过mAbs.去中和 (61.8%).
- 所有五个表面循环 (HI,DE,EF,FG,BC) 对于通过各种mAbs. 中和至关重要.
- 确定了两种过度代表的mAb类型:一种使用IGHV2-70/IGLV1-40并结合所有五个循环,另一种使用IGHV4-34/DH3-16*02,结合DE/FG循环.
- 化EM检测显示了这些mAb类型的独特结合模式,这表明它们有共同的发育途径和免疫主导表位.
结论:
- 人类mAbs对HPV16的中和涉及多个L1表面循环,其中FG循环是最常见的目标.
- 独特的结构特征和结合点是HPV16特异性中和抗体的主要特征.
- 这些发现为HPV的抗体识别提供了洞察力,并为疫苗设计和治疗策略提供了信息.
相关概念视频
Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Antigens Involved in Adaptive Immunity
1.3K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.3K


